The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2016 | The current research on momelotinib for myelofibrosis
Haifa Kathrin Al-Ali, MD from University of Leipzig, Leipzig, Germany discusses momelotinib for myelofibrosis at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. Momelotinib is a JAK1 and JAK2 inhibitor and even though only data from the Phase I and Phase II trials is available, there have been positive results similar to those seen with ruxolitinib. Momelotinib has shown to have an essentially positive impact with patients with anemia and transfusion dependency. Momelotinib differs from ruxolitinib in this regard and this is thought to be due to momelotinib’s inhibition of the hepcidin production pathway in hepatocytes. However, momelotinib has a specific side effect, peripheral neuropathy, which occurs in approximately every second patient.
